Coronavirus disease 2019 therapeutics I: COR‑101 neutralizing antibodies for the treatment of Coronavirus disease 2019 patients: Phase Three study and scaling of the manufacturing process for commercial supply

✏️ Listing Description:

📁 Related Knowledgebase Resources

.

📁 Related Innovation Offers

.

📁 Related Funding and Finance Opportunities

.

Access Restricted

This knowledgebase resource is only fully available for users with Personal Access or Professional Access.

Already member? - Login Get instant access (19,99 € / month) See your options Book a Meeting